AU2003219100A1 - Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3 - Google Patents

Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3

Info

Publication number
AU2003219100A1
AU2003219100A1 AU2003219100A AU2003219100A AU2003219100A1 AU 2003219100 A1 AU2003219100 A1 AU 2003219100A1 AU 2003219100 A AU2003219100 A AU 2003219100A AU 2003219100 A AU2003219100 A AU 2003219100A AU 2003219100 A1 AU2003219100 A1 AU 2003219100A1
Authority
AU
Australia
Prior art keywords
gsk
inhibition
preparation
pyrazolopyridazine derivatives
pyrazolopyridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219100A
Inventor
Robert William Ward
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003219100A1 publication Critical patent/AU2003219100A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003219100A 2002-03-21 2003-03-20 Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3 Abandoned AU2003219100A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0206723.9A GB0206723D0 (en) 2002-03-21 2002-03-21 Novel compounds
GB0206723.9 2002-03-21
PCT/EP2003/003171 WO2003080616A1 (en) 2002-03-21 2003-03-20 Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3

Publications (1)

Publication Number Publication Date
AU2003219100A1 true AU2003219100A1 (en) 2003-10-08

Family

ID=9933463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219100A Abandoned AU2003219100A1 (en) 2002-03-21 2003-03-20 Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3

Country Status (3)

Country Link
AU (1) AU2003219100A1 (en)
GB (1) GB0206723D0 (en)
WO (1) WO2003080616A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232669D1 (en) * 2001-04-30 2009-07-30 Vertex Pharma INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES
JP2006504755A (en) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Pyridazine compounds as GSK-3 inhibitors
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
BRPI0810496A2 (en) * 2007-04-09 2018-11-06 Hoffmann La Roche non-nucleoside reverse transcriptase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2701510B1 (en) * 2011-04-25 2017-02-15 Usher III Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2014066836A1 (en) * 2012-10-25 2014-05-01 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
EP4178580A1 (en) * 2020-07-09 2023-05-17 Usher III Initiative, Inc. Treatment of cancer, inflammatory diseases and autoimmune diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747776B2 (en) * 1998-10-30 2002-05-23 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
WO2003080616A1 (en) 2003-10-02
GB0206723D0 (en) 2002-05-01

Similar Documents

Publication Publication Date Title
AU2003219100A1 (en) Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
AU2003233010A1 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
HK1098737A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003203170A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
AU2003260984A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2003233820A1 (en) Method for the treatment of starch
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003289176A1 (en) 1,3-benzothiazinone derivatives, process for producing the same and use thereof
AU2003245880A1 (en) Process for the preparation of thioalkylamine derivatives
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003225426A1 (en) Process for the preparation of urea
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003303019A1 (en) Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase